1. Home
  2. NTLA vs SLVM Comparison

NTLA vs SLVM Comparison

Compare NTLA & SLVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.82

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

HOLD

Current Price

$49.78

Market Cap

1.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTLA
SLVM
Founded
2014
1898
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Paper
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
NTLA
SLVM
Price
$13.82
$49.78
Analyst Decision
Buy
Buy
Analyst Count
19
2
Target Price
$17.32
$54.00
AVG Volume (30 Days)
6.5M
263.3K
Earning Date
02-26-2026
02-12-2026
Dividend Yield
N/A
3.57%
EPS Growth
N/A
N/A
EPS
N/A
4.36
Revenue
$57,528,000.00
$3,431,000,000.00
Revenue This Year
$1.96
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$11.56
Revenue Growth
33.52
N/A
52 Week Low
$5.90
$37.52
52 Week High
$28.25
$82.04

Technical Indicators

Market Signals
Indicator
NTLA
SLVM
Relative Strength Index (RSI) 61.88 49.06
Support Level $13.86 $49.04
Resistance Level $17.09 $51.56
Average True Range (ATR) 1.28 1.66
MACD 0.29 -0.16
Stochastic Oscillator 52.80 45.59

Price Performance

Historical Comparison
NTLA
SLVM

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

Share on Social Networks: